Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will hold one-on-one investor meetings at the Lake Street Capital Markets "BIG10" Conference in New York City on September 10, 2026.

The event runs in a one-on-one meeting format only. Profound will not offer a webcast, so investors who want access to management must attend the meetings in person.

Toronto – October 12, 2026 -- Profound Medical Corp. expects third-quarter 2026 revenue of $9.8 million to $10.0 million, roughly 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.

Revenue nearly doubles year over year and almost quadruples sequentially

The preliminary, unaudited range implies growth of approximately 85% to 89% from $5.3 million in the third quarter of 2025. Compared with $2.5 million in the second quarter of 2026, revenue is expected to rise approximately 292% to 300%.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has signed a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX), giving it wider access to urologists in the U.S. and internationally through a strategic partner in prostate cancer imaging.

Farnborough – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) placed a direct order for 15 Boeing 787-9 Dreamliners, taking its fleet of 787 aircraft to approximately 140. The lessor announced the order at the 2026 Farnborough International Air Show.

AerCap schedules deliveries of the 15 aircraft through 2033

The aircraft will be delivered through 2033, giving the lessor a long-dated widebody pipeline. AerCap selected GE Aerospace's GEnx-1B engines to power all 15 jets.

DUBLIN – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) has filed its interim financial report for the quarter ended June 30, 2026, with the U.S. Securities and Exchange Commission, including unaudited condensed consolidated financial statements and notes.

AerCap submits the second-quarter filing on Form 6-K

The report was filed as a Form 6-K. It is available in the Investors section of AerCap's website and on the SEC's website. The announcement itself contained no revenue, earnings or fleet figures; those details sit in the filing.

Dublin – October 12, 2026 -- AerCap Funding Designated Activity Company, a wholly-owned subsidiary of AerCap Holdings N.V., has priced $1.5 billion of senior notes split evenly between a 2030 and a 2033 maturity.

AerCap Funding splits the $1.5 billion offering into two $750 million tranches

The 5.500% Senior Notes due 2030 and the 5.875% Senior Notes due 2033 each carry a principal amount of $750 million. The 2033 tranche pays a coupon 0.375 percentage points higher than the 2030 tranche in exchange for three additional years of maturity.

Dublin – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) will publish its third quarter 2026 financial results before U.S. markets open on Wednesday, October 28, 2026, and discuss them on a conference call at 8:30 a.m. Eastern Time the same day.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV), ending a dual listing it says no longer justifies its cost. The company will keep its primary listing on Nasdaq (XRTX) and its Frankfurt listing (ANU).

XORTX, a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease, will announce the timing of the delisting in a separate press release.

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX) has appointed Mika Grasso, 28, as co-CEO responsible for finance and public markets, and says it aims to advance its lead gout program, XRx-026, toward marketing approval over the next 18 months.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has appointed Depesh Narotam, a financial services executive with more than 20 years of experience, to its board as an independent director effective July 27, 2026.

Board determines Narotam meets Nasdaq and Canadian independence standards

The board determined that Narotam, 43, is independent under applicable Nasdaq listing standards and Canadian securities laws. He also joins the board's Compensation, Governance and Nominating Committee.